Résultats de la recherche
10
Tout
Rechercher les filtres
Mot-clé
ophthalmology
Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
24 mars 2025 07h05 HE
|
Clearside Biomedical, Inc.
- Suprachoroidal Delivery Develops as Promising Mainstream Procedure for Treating Multiple Macular Diseases - - SCS Microinjector® Provides Targeted and Compartmentalized Delivery of Therapeutics...
Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit
20 mars 2025 07h05 HE
|
Clearside Biomedical, Inc.
- Post-Hoc Analyses Provide Comparative Data on Rescue Criteria and Intervention-Free Rates for Tyrosine Kinase Inhibitors (TKIs) in Wet AMD Development - - Unique Ability to Re-Dose CLS-AX vs Rescue...
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema
18 mars 2025 08h02 HE
|
Ocugen
OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18,...
Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025
12 mars 2025 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to...
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD
06 mars 2025 07h05 HE
|
Clearside Biomedical, Inc.
- CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD - - Flexible Dosing and Extended Duration would be Important Differentiators from Existing Approved Therapies and Other...
RetinalGenix Technologies to Participate at the 37th Annual Roth Conference
06 mars 2025 06h00 HE
|
RetinalGeniX Technologies, Inc.
RetinalGenix Technologies to Participate at 2025 Roth Conference and will discuss patented remote monitoring high-resolution retinal imaging and biomarkers
Physicians’ Education Resource® unveils Retina Resource, a comprehensive educational hub for retina specialists and eye care professionals
05 mars 2025 10h00 HE
|
Physicians' Education Resource®
CRANBURY, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Physicians’ Education Resource (PER®) is excited to announce the launch of Retina Resource, a comprehensive source of cutting-edge education and...
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results
05 mars 2025 07h02 HE
|
Ocugen
Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three yearsCompleted dosing in...
Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease
03 mars 2025 09h00 HE
|
Ocugen
MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...
NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award
27 févr. 2025 16h03 HE
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that it has been...